*Disseminated on Behalf of Quantum BioPharma Ltd.
Jeff Ackerman Initiates Coverage On Quantum BioPharma (NASDAQ: QNTM) Starting This Morning—Thursday, August 7, 2025 Here's Why (QNTM) Just Hit Our Radar…
Limited Float: With Fewer Than 2.6M Shares Available, (QNTM) Has The Potential For Big Moves—Even With Small Shifts In Demand Recent Momentum: (QNTM) Just Moved (Approx.) 71% In The Past Month, And Over (Approx.) 1,300% In Six Months After Our Last Highlight.
Analyst Target: Singular Research Raised Its 12-Month Target For (QNTM) To $35.50, Indicating (Approx.) 42% Upside Potential From Its Recent Range.
Technical Strength: (QNTM) Is Trending Above All Major Moving Averages Tracked By Barchart Across Short-, Mid-, And Long-Term Timeframes. Major Clinical Milestone: (QNTM) Reported Positive Phase 1 MAD Results For Lucid-MS, Showing Safety And Tolerability In Healthy Participants. Take A Look At (QNTM) This Morning While It's Still Early… August 7, 2025 Just In | (QNTM) Up Approx. 160% Since Q1—Q2 Filing Hits the Wire
Dear Reader, The last time we brought (QNTM) to your radar, it went on to post a move of approximately 1,300% over the following six months. And from the end of Q1 to the close of Q2, it moved approximately 160%—from $7.71 to $20.25. And based on what just hit the wire… it may be time to pull it up again. This morning, Quantum BioPharma (NASDAQ: QNTM) reported what may be one of the strongest financial quarters we've seen from a clinical-stage company this year—showing rising assets, cry-pto gains, debt elimination, and multiple near-term catalysts across its brain health pipeline and consumer product verticals. (QNTM) nearly tripled during the quarter alone—now add in: - Zero debt from converted debentures
- Over $500K in cry-pto gains
- Advancing trials for its MS program and PET diagnostic with Mass General
- A pre-IPO setup for its al-co-hol detoxification asset unbuzzd™—without dilution
…and you can see why this one's flashing again.
Read the full news release here
Fresh off a headline-making clinical milestone, the company has just announced positive results from its Phase 1 Multiple Ascending Dose (MAD) clinical trial for Lucid-MS, a first-in-class therapeutic candidate designed to target the underlying mechanism of multiple sclerosis (MS). The study's Clinical Study Report (CSR) concluded that Lucid-MS was safe and well-tolerated in healthy participants, removing a major early-stage hurdle and paving the way for the next critical step — an Investigational New Dr-ug (IND) application with the FDA, expected in Q4 2025. With several programs advancing in parallel, (QNTM) is entering a stretch where developments could come fast — and each one could matter. Analyst Coverage
Singular Research recently reaffirmed its bullish rating on (QNTM), lifting its 12-month target to $35.50 from $12.90. Key drivers for the increase include: - Upcoming IND filing for Lucid-MS
- FSD202 Phase 2 trial initiation
- Progress toward the Unbuzzd Wellness IPO
- Added upside from contingent value rights tied to potential litigation proceeds exceeding $700M
Singular's target suggests around 42% upside potential from (QNTM)'s recent $25 range. According to Yahoo, (QNTM)'s public float sits below 2.6M shares — a situation where even a small shift in demand could spark the potential for big moves. In fact, the last time we brought you (QNTM) was on the evening of Thursday, December 19, 2024; by the next morning it was trending at around $2.70, and over the following six months it climbed to $38.25 on June 20 — an approximate move of more than 1,300%. 
Over the past month, (QNTM) has already shown what a shift in momentum can look like — moving approximately 71% from $16.39 on July 9 to $28.15 on August 4. That kind of move in a short window, paired with the latest developments, has only amplified interest. According to Barchart's technical analysis tool, (QNTM) is currently trending above every major moving average it tracks, spanning short-, mid-, and long-term timeframes. This kind of alignment could be signaling the potential for continued momentum — and it's a key reason why (QNTM) is topping our watchlist right now. A Pipeline Anchored by Breakthrough Science
Quantum BioPharma isn't your typical clinical-stage biopharmaceutical name. Through its wholly owned subsidiary Lucid Ps-ych-eceut-icals Inc., the company is developing Lucid-MS, a patented New Chemical Entity with a unique non-immunomodulatory approach. Preclinical data shows the compound's ability to prevent and even reverse myelin degradation — a hallmark of MS and other neurodegenerative diseases. Unlike conventional MS therapies that primarily modulate the immune system, Lucid-MS is aimed at neuroprotection — a therapeutic angle many experts believe will be the next frontier in treating demyelinating diseases. And now, with both Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) trials complete, the company is advancing toward Phase 2 efficacy trials in MS patients — a move that could put it on the radar of major healthcare players. Beyond MS: A Diversified Portfolio
While Lucid-MS is the scientific flagship, (QNTM)'s story extends well beyond multiple sclerosis. FSD202 – Recently cleared for a Phase 2 trial in nociplastic pain associated with Idiopathic Mast Cell Activation Syndrome (MCAS). There's currently no cure for MCAS, and FSD202 could address a substantial unmet need. - Unbuzzd™ – A science-backed, rapid alcohol detoxification beverage designed to accelerate alcohol metabolism, restore mental alertness, and support faster recovery. According to Grand View Research, the global hangover cure products market was valued at $2.05B in 2022 and is projected to grow to $6.2B by 2030 at a 14.8% CAGR. As the first-to-market product in this category backed by clinical results, Unbuzzd™ is positioned to capture a share of that growth.
- (QNTM) earns 7% royalties up to $250M in cumulative payments (then 3% in perpetuity) and retains 100% of pharmaceutical and medical rights to develop similar formulations for clinical use.
- Strategic In-vest-ments – Managed through FSD Strategic In-vest-ments Inc., holding secured loans backed by residential and commercial property.
This combination of therapeutic innovation, consumer health products, and asset-backed in-vest-ments provides multiple potential value streams — rare for a company of this size and stage. Signals You Can't Ignore
This latest CSR announcement is more than just a clinical update — it's a potential inflection point. The removal of early-stage safety concerns for Lucid-MS not only strengthens the case for FDA IND submission, but also signals to the market that the company's MS program is moving closer to patient trials. When you combine that with: - A multi-asset pipeline
- Near-term catalysts across multiple programs
- Ongoing analyst coverage with significantly higher price targets
- A low-float structure
…it's clear why (QNTM) just hit our radar. 7 Reasons Why (QNTM) Is Topping Our Watchlist This Morning
—Thursday, August 7, 2025
1. Very Limited Float: with fewer than 2.6M shares in the public float, (QNTM) has the kind of structure where even a small shift in demand could lead to the potential for big moves. 2. Recent Momentum: over the past month, (QNTM) has moved approximately 71% from $16.39 on July 9 to $28.15 on August 4, highlighting the potential for short-term momentum. Last time we highlighted this profile it made an approximate move of more than 1,300% in 6 months. 3. Analyst Target: Singular Research lifted its 12-month target for (QNTM) to $35.50 from $12.90, citing multiple near-term catalysts. Singular's target suggests around 42% upside potential from its recent range. 4. Technical Strength: (QNTM) is currently trading above all major moving averages tracked by Barchart, spanning short-, mid-, and long-term timeframes. 5. Major Clinical Milestone: (QNTM) just reported positive results from its Phase 1 Multiple Ascending Dose trial for Lucid-MS, confirming safety and tolerability in healthy participants. 6. Multi-Asset Pipeline: beyond Lucid-MS, (QNTM) is advancing FSD202 toward a Phase 2 trial for MCAS and maintains a commercial stake in Unbuzzd™. 7. Diverse Revenue Paths: with clinical-stage programs, consumer health royalties, and secured property-backed in-vest-ments, (QNTM) has multiple avenues for potential value creation. See the company's corporate presentation here. Take A Look At (QNTM) This Morning While It's Still Early…
With a public float of under 2.6M shares, (QNTM) has the kind of structure where even a small shift in demand can lead to the potential for big swings. Over the past month, it's moved approximately 71%, and the last time we covered this profile it went on to showcase an approximate 1,300% move over six months. Analyst coverage has recently lifted the 12‑month target to $35.50, which suggests 42% upside potential from its recent range. On the technical side, (QNTM) is trending above all major moving averages tracked by Barchart, reinforcing its current potential for continued momentum. The company just cleared a major clinical milestone with positive Phase 1 MAD results for Lucid‑MS, and it's advancing a multi‑asset pipeline that includes FSD202 and its commercial stake in Unbuzzd™. With multiple revenue paths in play — spanning clinical programs, consumer health royalties, and secured in-vest-ments — the foundation for further developments is in place. This just landed on our radar, and the setup is hard to ignore. We have all eyes on (QNTM) this morning. Take a look at (QNTM) while it's still early. With momentum building across both its pipeline and operations, it's no surprise Quantum BioPharma (NASDAQ: QNTM) is lighting up the radar again this morning. Keep an eye out for my next update—it could be hitting any moment. Sincerely, Jeff Ackerman
Managing Editor
Stock News Trends
| 
Post a Comment
Post a Comment